mRNA for Life

mRNA for Life, Inc. was a biotechnology subsidiary of Ludwig Enterprises, Inc. (now Revealia, Inc.) that specialized in mRNA-based diagnostic technologies and personalized health solutions. The company developed a non-invasive buccal swab method to collect mRNA from cheek cells, aiming to measure an "mRNA Inflammatory Index" composed of various genetic biomarkers. This technology was intended to facilitate the early detection and monitoring of chronic inflammatory diseases, including cancer, diabetes, and cardiovascular conditions. Additionally, the company planned to produce "Genetic Centric Supplements" tailored to individual diagnostic results. While the subsidiary was dissolved in October 2024, its intellectual property and diagnostic approach continue to underpin the parent company's development of the Revealia™ cancer screening platform.